SCHEMBL31146193

SCHEMBL31146193

Cc1cc(=O)[nH]c2ccc(F)c(C(F)(F)F)c12

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 1/20 0.44
▸ AR P10275 11/20 0.43
▸ LMNA P02545 1/20 0.42
▸ TP53 P04637 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ TNKS2 Q9H2K2 3/20 0.39
▸ MAPK14 Q16539 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ TNKS O95271 1/20 0.38
▸ CYP19A1 P11511 1/20 0.37
▸ NQO2 P16083 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31146192 0.71 DAO (0.31) —
SCHEMBL24756836 0.70 AR (0.44) ARLMNATP53SMN1; SMN2TNKS2
SCHEMBL31146124 0.69 ERN1 (0.49) ERN1ARLMNATP53SMN1; SMN2
SCHEMBL8904877 0.67 GRIN2D (0.53) —
SCHEMBL4145604 0.67 AR (0.51) AR
SCHEMBL31146294 0.67 PGR (0.40) ERN1ARLMNATP53SMN1; SMN2
SCHEMBL31146038 0.66 AR (0.36) ERN1ARLMNACYP19A1NQO2
SCHEMBL4131580 0.66 AR (0.51) ERN1ARLMNATP53SMN1; SMN2
SCHEMBL16511236 0.66 TNKS2 (0.56) ARLMNATP53SMN1; SMN2TNKS2
SCHEMBL1771743 0.66 AR (0.48) AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688748-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2026-02-11 — — EP disclosed
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2026-01-08 — — US disclosed
US-12448369-B2 Quinolinone amide compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-10-21 — — US disclosed
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 — — US disclosed
WO-2024206339-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448369-B2 Quinolinone amide compounds and uses thereof TNNI3, TNNT2, COQ8A ERN1 4350/4885AR 3577/4885LMNA 748/4885
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, COQ8A ERN1 4350/4885AR 3577/4885LMNA 748/4885
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNT2, TNNI3, TNNC1 ERN1 2489/4885AR 856/4885LMNA 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback